Natalizumab and HSV meningitis
- First Online:
- Cite this article as:
- Shenoy, E.S., Mylonakis, E., Hurtado, R.M. et al. J. Neurovirol. (2011) 17: 288. doi:10.1007/s13365-011-0027-4
- 171 Downloads
Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn’s disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.